Search results
Added:
7 months ago
ACC 2025 - EVOLUT Low-Risk findings show the Medtronic TAVR system is a safe and effective treatment for aortic stenosis vs surgical valves at five years.Dr Michael Reardon (Houston Methodist, Texas, US) joins us onsite at ACC to discuss the EVOLUT Low Risk trial (NCT02701283; Medtronic Cardiovascular), investigating the safety and effectiveness of the Medtronic TAVR system compared to surgical…
View more
Start date:
Oct 30, 2025
Join Dr Matthias Götberg (Skane University Hospital, SE), Dr Karim Al-Azizi (Baylor Scott & White Legacy Heart Center, US) and Prof Farrel Hellig (Sunninghill Hospital, ZA) in this webinar as they delve into the evolving field of ultra-low contrast PCI. The faculty will explore how interventional cardiologists can achieve procedural precision while significantly reducing contrast usage.Through a…
View more
Added:
1 year ago
In this interview, Dr Masaru Seguchi (German Heart Centre, DE) explains the aim of the BIOMAG-I OCT analysis, what the findings were and what the data means for the future of cardiology.
View more
TCT 23: EVOLUT Low-Risk
Added:
2 years ago
Video
Added:
1 year ago
TCT 23 - In this short virtual interview, we are joined by Dr Martin B Leon (Columbia University Medical Center, US) to discuss the 5-year outcomes from Edwards' PARTNER 3 low-risk trial (NCT02675114).PARTNER 3 is a randomized, prospective, multicenter trial that aimed to determine the safety and effectiveness of the SAPIEN 3 transcatheter heart valve in patients with severe calcific aortic…
View more
Added:
5 months ago
EuroPCR25 - Findings from TRINITY trial show favourable outcomes with the LuX-Valve Plus TTVR system in high-risk patients with severe tricuspid regurgitation.We are joined by Prof Thomas Modine (CHU de Bordeaux, Bordeaux, FR) to discuss key findings from the TRINITY trial. This prospective, single-arm, multi-center study evaluated the LuX-Valve Plus transjugular tricuspid valve replacement…
View more
Added:
4 months ago
New York Valves 2025 - Early outcomes from an observational study with the PASCAL System show a 97% device success rate.Dr Santiago Garcia (The Christ Hospital, Cincinnati, OH, US) joins us to discuss a novel TEER device system. This observational study investigated the use of the PASCAL Prescision system in over 2000 patients from the STS/ACC/TVT registry over a period of two years.Findings…
View more
Added:
2 weeks ago
TCT 2025 - Sub-anlysis findings showed positive safety and efficacy outcomes of the PASCAL Precision system in degenerative mitral regurgitation (DMR) patients.Dr P Kasi Ramanathan (Promedica Toledo Hospital, US) joins us on-site at TCT 2025 to share the findings from a sub-analysis looking at the affect of implant location and leaflet lesion location on the safety and effectiveness of the PASCAL…
View more
Added:
2 weeks ago
Source:
Radcliffe Cardiology
Long-term data from the PARTNER 3 trial show no significant differences in key clinical outcomes at 7 years between transcatheter aortic-valve replacement (TAVR) and surgical aortic-valve replacement (SAVR) for low-risk patients with severe, symptomatic aortic stenosis.¹ This extended follow-up provides crucial insights into the durability and long-term safety of both procedures in this patient…
View more
Added:
1 year ago